All In Biotech

Drug Trial Radar · NCT01703052

Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)

A Placebo-controlled Double-blind Single and Repeated Ascending Dose Study to Investigate the Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jul 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

74

Actual

Start

Jul 2011

Primary completion

May 2012

Study completion May 2012

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Oct 10, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to investigate the safety, tolerability and pharmacokinetics of inhaled CHF 6001 after single and multiple doses in healthy volunteers.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • CHF 6001 SD or placeboDrug

    Dry Powder Inhaler

  • CHF 6001 MD or placeboDrug

    Dry Powder Inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events, adverse drug reactions, serious adverse events.Time frame: After 7 days of treatment
  2. Vital signsTime frame: After 7 days of treatment
  3. 12-lead ECGTime frame: After 7 days of treatment
  4. 24h ECG HolterTime frame: After 7 days of treatment
  5. FEV1Time frame: After 7 days of treatment
  6. Blood and urine Laboratory testsTime frame: After 7 days of treatment
  7. Body weightTime frame: After 7 days of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Clinical

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.